- Active not recruitingPHASE2, PHASE3
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
This study is testing a new drug called imetelstat for certain types of Myelodysplastic Syndromes (MDS). It aims to see if the drug can help reduce the need for blood transfusions and is safe to use for people whose current treatment hasn't worked.
For: Myelodysplastic SyndromesUnited States · Belgium · Canada - Active not recruitingPHASE2
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
This study looks at a new drug, imetelstat, for people with specific types of blood cancer (high-risk MDS or AML) whose previous treatments haven't worked well. It aims to see how effective and safe imetelstat is in improving blood conditions.
For: Myelodysplastic Syndromes · Acute Myeloid LeukemiaAustralia · France · Germany